Business Update
Expanded access program for Rexin-GTM provides genetic medicine to cancer patients
Published in Gene Therapy Weekly, May 11th, 2006
Following the landmark approval of Rexin-GTM for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila. Dr. Erlinda Maria Gordon, MD, chairman, said, "We are pleased that the value of Rexin-GTM in the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-05-11)
More Articles from Gene Therapy Weekly
- Antisense Technology
Antisense oligodeoxynucleotides can be delivered from cationically modified polymer films - Antisense Technology
Morpholino antisense oligonucleotides inhibit Oct4 expression - Cancer Gene Therapy
Breast cancer cell invasiveness is affected by matrix metalloproteinase - Gene Therapy
Calcitonin gene-related peptide receptor is activated by gene transfer - Gene Transfer
Gene transfer and enzyme replacement eliminates abnormal fibroblast sialylglycoproteins - Alveolar Cancer
Bronchoalveolar cell carcinoma is reduced by gene-modified dendritic cells - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
